IQVIA Holdings Inc. $IQV is Act Two Investors LLC’s 5th Largest Position

Act Two Investors LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.3% in the fourth quarter, HoldingsChannel reports. The firm owned 164,754 shares of the medical research company’s stock after selling 5,566 shares during the period. IQVIA comprises about 6.3% of Act Two Investors LLC’s portfolio, making the stock its 5th largest holding. Act Two Investors LLC’s holdings in IQVIA were worth $37,137,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Boston Partners purchased a new position in IQVIA in the third quarter valued at about $676,698,000. Norges Bank purchased a new position in IQVIA in the fourth quarter valued at about $497,445,000. AQR Capital Management LLC boosted its holdings in IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Citigroup Inc. raised its stake in IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after buying an additional 475,557 shares in the last quarter. Finally, Invesco Ltd. raised its stake in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after buying an additional 367,204 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.5%

Shares of IQVIA stock opened at $182.03 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s 50 day simple moving average is $170.34 and its 200-day simple moving average is $196.18. The stock has a market capitalization of $30.38 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.74 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $136.41 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several analysts have issued reports on IQV shares. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday, February 6th. JPMorgan Chase & Co. cut their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.